Perturbations of the precise space-time coordination of cellcycle events lead to genomic instability causing cancerous growth or death of progeny cells. 1 Cancer cells illegitimately pass through tightly controlled cell-cycle transitions and gain a selective growth advantage over normal cells. Although strict regulation of centrosome duplication and inheritance is pivotal to the correct execution of cell division, centrosome amplification, either due to the deregulated centrosome duplication or cytokinetic failure, frequently occurs in cancer cells and correlates with chromosomal instability.
Microtubule-binding drugs also produce abnormalities in centriole structure and centrosome duplication 2 in response to cell-cycle arrest 3 or because of damaged or incompletely replicated DNA during mitosis. 4 Interestingly, Drosophila and vertebrate cells in culture harboring extra centrosomes initially form multipolar spindles in early mitosis, 5 but eventually divide bipolarly yielding division-competent progeny. The extra centrosomes cluster at two dominant spindle poles and/or become progressively inactivated. [6] [7] [8] However, in cells in which extra centrosomes failed to cluster, the resulting multipolar division invariably produced inviable progeny. These observations have raised the possibility that induction of spindle multipolarity could be a potential chemotherapeutic strategy.
Anti-tubulin agents, such as taxanes and vincas are extensively used for clinical treatment of human malignancies. 9 However, they either overpolymerize (taxanes) or depolymerize microtubules and form paracrystals (vincas), thereby impairing crucial microtubule functions and causing devastating toxicities. 9 Noscapinoids represent a novel class of microtubule-modulating agents that avoid the harsher effects of currently available tubulin-binding chemotherapeutics by preserving the total polymer mass of tubulin. [10] [11] [12] The parent molecule, noscapine, a plant-derived antitussive alkaloid, is in Phase I/II clinical trials for treatment of multiple myeloma. In silico molecular modeling efforts to rationally design and chemically synthesize better noscapine analogs have led to the identification of more potent noscapine derivatives. [13] [14] [15] In particular, 9-bromonoscapine (EM011) binds tubulin with greater affinity than noscapine, and is effective even against drug-resistant xenograft tumors without any detectable toxicity. [16] [17] [18] [19] [20] Therefore, noscapine and its analogs are known as 'kinder and gentler' microtubulemodulating agents. 21 EM011 treatment causes a G2/M arrest in cancer cells followed by apoptotic cell death. [16] [17] [18] [19] [20] [21] [22] However, the relationship between mitotic-block and cell death has remained elusive. In order to understand EM011's mode of action, we examined how this drug induces perturbations in the coordination of mitotic events causing cell-cycle stasis, and then tips the outcomes in favor of cell death rather than continued, increasingly aberrant and aggressive proliferation. We determined the EM011's effects on cell-cycle progression and spindle biogenesis and analyzed how it induces apoptosis. Our data show that EM011 treatment reduces microtubule dynamicity and deregulates the centrosome duplication cycle, causing centrosome amplification and spindle multipolarity. Spindle multipolarity in turn, produces multiple catastrophic cellular outcomes, culminating in apoptosis induction.
Results
EM011 preserves microtubule ultrastructure. Error-free mitotic progression requires precise regulation of microtubule dynamics. As both microtubule-stabilizing and -destabilizing agents suppress spindle dynamics, 23, 24 we first asked whether EM011 mediates cytotoxicity by perturbing dynamic instability of interphase microtubules in living GFPtubulin expressing MCF-7 cells (Supplementary Movie-1 (control) and Movie-2 (treated), time-lapse movies). In contrast to control cells in which microtubules alternated between phases of growth and shortening, with intervening 'pause' phases, EM011 treatment attenuated microtubule dynamics as indicated by largely unaltered position of microtubule ends at the cell periphery (Figure 1ai ). Figure  1aii shows life-history traces of microtubules from control and treated cells. Supplementary Table 1 shows quantitative analysis of microtubule growth, shortening, frequencies of catastrophe and rescue and average duration of pause phase. We found that EM011 reduced overall dynamicity by B72% and increased pause duration by B76%. Thus EM011 decreases the number of dynamic events in the life history of a microtubule without affecting its long-term existence.
Unlike taxanes and vincas that often exert extreme effects on microtubules, EM011 preserves the monomer/polymer ratio of tubulin at concentrations as high as 100 mM.
11,13 Using immunofluorescence confocal microscopy and transmission electron microscopy, we found that EM011 did neither perturb the radial-array of microtubules nor their ultrastructural morphology in interphase cells, compared with vehicletreated cells (Figure 1b) . In contrast, 0.01 mM paclitaxel overpolymerized microtubules and bundled them into continuous sheets (Figure 1b) . Hence, EM011 treatment merely dampened microtubule dynamics without causing any detectable structural changes to the microtubule cytoskeleton.
EM011 modulates microtubule dynamics by affecting microtubule plus-end proteins. Changes in microtubule dynamicity are generated by microtubule-associated proteins and plus-end-tracking proteins that are crucial for many microtubule-regulated processes. Among the latter, EB1 (end binding protein-1) is a core regulator of microtubule plus-end function. 25 We examined whether EM011-induced reduction in microtubule dynamicity correlated with any changes in EB1 localization in HeLa cells. In control cultures, conspicuous GFP-EB1 comets decorated the growing plusends of microtubules (Figure 1c ) as expected. 25 In contrast, EM011 treatment reduced the size of EB1 comets that appeared as fine puncta dispersed throughout the cell (Figure 1c ). This phenotype could reflect a tubulin and/or microtubule conformation change that alters the binding affinity or the number of EB1-binding sites on microtubules. Alternatively, EM011 may directly inhibit EB1 binding to microtubules or EB1 stability. In either case, a drastic reduction in the amount of microtubule-bound EB1 is likely to significantly impact the behavior of microtubule plus-ends. Next, we examined how EM011 affected localization of CLIP-170 (cytoplasmic linker protein-170), another microtubule plus-end tracking protein. Inhibition of microtubule dynamics by anti-mitotic drugs can disrupt the microtubule association of CLIP-170. 26 We observed that in contrast to vehicle-treated cells in which CLIP-170 localizes to microtubule plus-ends as distinct comets, EM011 treatment abolished CLIP-170's plus-end association and caused its intracellular dispersal (Figure 1c) , an effect strikingly reminiscent of EM011's effect on EB1-GFP localization. Thus, EM011 causes dramatic changes in overall microtubule dynamicity and in particular, may impair normal behavior of microtubule plus-ends, without affecting its gross morphology.
EM011 induces mitotic and not G2 arrest. EM011 inhibits proliferation of various cancer cells through induction of G2/ M arrest. [16] [17] [18] [19] [20] 22 To explore cell-cycle-specific events that result in mitotic-block and subsequent cell death, we chose cervical cancer HeLa cells, owing to their relatively strong checkpoints. A standard sulforhodamine-B assay reported the IC 50 of EM011 in HeLa cells to be 4.5 mM (data not shown). We next examined time-dose effects (10 and 25 mM EM011) on cell-cycle progression of HeLa cells flowcytometrically (Figure 2a ) and quantitated the proportion of cells in each cell-cycle phase (Figure 2b ). Our results indicated that upon drug treatment, cells transit through S-phase and accumulate in G2/M-phase (with 4N DNA) maximally at 24 h (B72%) for 10 mM and 18 h (B80%) for 25 mM EM011 (Figure 2c ). Furthermore, two-color flowcytometry showed that the mitotic population peaked to B56% (10 mM EM011, 24 h) and B63% (25 mM EM011, 18 h) indicating time-dependent accumulation of mitotic cells at both doses (Figure 2d ).
EM011 induces formation of multipolar spindles through centrosome amplification. We next visualized formation of highly aberrant multipolar mitotic spindles in EM011-treated cells using immunofluorescence confocal microscopy. We quantitated the frequencies of abnormal spindles using a well-accepted classification scheme, 23 at different drugdosages over time. Figure 1) . This is a unique edge of EM011, compared with conventional tubulin-binding drugs that polymerize or depolymerize microtubules at concentrations higher than their IC 50 . 24 Figure 3aii shows quantitation of frequencies of drug-induced spindle abnormalities (Types I-III). All cell-cycle stages appeared normal in control cells (Figure 3b and Supplementary Movie-4). In drug-treated cultures, mitotic cells with bipolar, as well as multipolar spindles (Supplementary Figure 2a) , displayed defects in chromosome congression to the mid-plate. Concomitant with the appearance of multipolar spindles, the kinase activity of Aurora B increased ( Supplementary  Figure 2b) , suggesting presence of aberrant kinetochoremicrotubule attachments. 27 Further evidence for the same came from the strong increase in BubR1 staining in EM011-treated cells (Supplementary Figure 2c , top-row) compared with controls. An increase in BubR1 phosphorylation (Supplementary Figure 2d) , implied a lack of tension and/or existence of aberrant kinetochore-microtubule connections Figure 1 'Kinder and gentler' effects of EM011 on microtubules. Dynamic instability behavior of fluorescently labeled interphase microtubules in the thin lamellar edge of MCF-7 cells expressing GFP-tubulin was imaged by time-lapse microscopy.(ai) Time-lapse sequence of video frames, 3 s apart, showing ends of microtubules near the cell periphery in vehicle-treated control (top) and 10 mM (bottom) EM011-treated MCF-7 GFP-tubulin cells. In the control cell, white and green arrows indicate two microtubules that undergo growing and shortening events, respectively. In the EM011-treated cell, white-arrowhead indicates two microtubule ends the positions of which did not change significantly over time. (aii) The positions of the microtubule ends near the cell periphery were tracked over time to generate life-history plots in the absence (top) or presence (bottom) of 10 mM EM011 from which microtubule dynamic instability variables were derived. The life-history traces of control microtubules show extensive length changes, whereas those of treated cells are nearly flat, indicating marked dampening of dynamics in the presence of EM011. Graphs, lengths of excursions made by individual microtubule ends over time. (b) EM011 does not perturb the morphology of microtubules as assessed by light and electron microscopy. Confocal immunomicrographs (toppanels) of cells with microtubules (green) and DNA (red) showing that 0.01 mM paclitaxel treatment overpolymerized and bundled microtubules in 2 h, evident by dense green sheet-like structures (top-middle). However, a 2-h treatment with 10 mM EM011 had no effect on the overall morphology of microtubules (top-right). The radial-array of interphase microtubules was maintained, and microtubules appeared similar to control microtubules (top-left). Transmission electron microscopy (bottom-panels) revealed that EM011 does not affect the ultrastructure of microtubules as compared with controls (see black-arrows). Paclitaxel-treated microtubules showed bundling (black-arrows, middle bottom-panel) and were closely packed into parallel-sheets. (c) Confocal fluorescence micrographs showing GFP-EB1 localization and CLIP-170 staining patterns (green) and nuclei (blue) in HeLa cells either transfected with GFP-EB1 (top-row) or labeled using anti-CLIP-170 antibody (bottom-row) following treatment with vehicle or 10 mM EM011. Scale bars: 10 mm. Scale bar for EM image: 250 nm EM011 induces centrosome amplification P Karna et al that caused spindle checkpoint activation. It is intriguing that 25 and 50 mM drug concentrations trigger conspicuous spindle multipolarity with a striking declustering of supernumerary centrosomes. Although suppression of microtubule dynamics may also be involved in multipolar spindle formation, other mechanisms such as interference with centrosome duplication 28 or dispersion of pericentriolar material to generate multiple microtubule-nucleating sites could result in multipolar spindles. 29 Microtubule-targeting drugs are also known to influence centrosome structure presumably by disrupting microtubule-dependent events in centrosome biogenesis. 2 Centrosome hyperamplification may also result from a prolonged S-phase 30 or cytokinesis failure. 31 However, our previously published data from various cell-types and data shown in Figure 2 emphasize that EM011-treated cells do not stall in S-phase. Also, the rapid emergence of multipolar phenotype rules out cytokinesis failure and consequent multinucleation as possible causes. As tightly regulated centrosome duplication is crucial to proper spindle biogenesis, we examined whether centrosomes could be one of the targets of EM011 and whether they contributed to the formation of multipolar spindles. We performed a-and g-tubulin staining to examine the presence of a true centrosome on each spindle pole. Although majority of vehicle-treated mitotic cells showed only two spots of g-tubulin per cell, supernumerary centrosomes were present at multiple spindle poles upon EM011 treatment (Figure 3ci and cii) and only B15% of EM011-treated mitotic cells showed two g-tubulin spots per cell. The frequencies of three g-tubulin spots and four or more g-tubulin spots per mitotic cell were B13-fold and B30-fold higher, respectively, in EM011-treated cells than in vehicletreated cells (Figure 3cii ). Thus, EM011 exposure causes centrosome amplification and the centrosomal component g-tubulin is present at each of the multiple poles.
EM011-induced supernumerary centrosomes contain 'real' centrioles. The detection of g-tubulin at spindle poles alone is not sufficient to unambiguously distinguish between centrosome overduplication and centrosomal matrix fragmentation. To distinguish between centrosome fragmentation and overduplication, we evaluated centriole profiles in EM011-induced supernumerary centrosomes using anti-centrin-2 antibodies. Centrin-2 localizes to distal-lumen of centrioles and their interconnecting fibers. 32 Although vehicletreated mitotic cells contained two centrosomes, each with (Figure 4b ). These data strongly suggested that multipolarity was in fact due to abnormal amplification of centrosomes that clearly contained centrioles. Interestingly, EM011 also caused untimely disengagement of centriole pairs and the intercentriolar distance was increased by B2.5 fold in drugtreated cells compared with controls (Figure 4c) . Occasionally, four spots of centrin-2 were visible in close proximity (Figure 4d ). However, alternative possibilities, viz, de novo synthesis or localization of centriolar components, 33 cannot be ruled out.
EM011 deregulates centrosome duplication. To further establish whether EM011 treatment caused misregulation of centrosome duplication cycle, we examined levels of Polo-like kinase 4 (Plk4), a central regulator of centriole biogenesis, the overexpression of which produces supernumerary centrioles. Conversely, RNA interference of Plk4 causes sequential reduction of centriole numbers, 34 indicating that intracellular Plk4 abundance must be tightly regulated to prevent untimely centriole reduplication. We found that Plk4 levels increased by 12 h post-treatment (Figure 5a ) when supernumerary centrosomes begin to appear, and rose further between 12-24 h of EM011 exposure. Plk4 accumulation, therefore, correlated with the period of centrosome duplication in drug-treated cells and may disrupt control of centriole numbers in these cells. Cyclin E levels also surged during the same time interval (Figure 5a ) as increase in Plk4 levels. This was noteworthy as in human cells, centriole overduplication through concurrent formation of multiple daughter centrioles at single maternal centrioles, requires cooperative action of both cyclin E/cdk2 and Plk4. 33 Next, we examined the levels of Aurora kinase A, the overexpression of which also leads to centrosome (Figure 5a ) and its kinase activity (Figure 5b) , concomitant with accumulation of Plk4 and cyclin E. Immunostaining also showed a massive increase in intracellular Aurora A levels in treated cells, compared with controls in which Aurora A was clearly restricted to centrosomes (Figure 5c ). Taken together, our data show that EM011-triggered induction of spindle multipolarity through centrosome amplification and declustering is accompanied by an accumulation of cyclin E, Plk4 and Aurora A kinases, factors that could be responsible for deregulation of centrosome duplication.
EM011-induced mitotic arrest is followed by an exit from mitosis. Among the possible outcomes of drug-induced mitotic arrest, one involves an erroneous exit from mitosis in the presence of drug, and subsequent transition into interphase. We thus evaluated the fate of chronically arrested mitotic cells. Our data show that although B56% cells were mitotically arrested at 24 h, B51% of cells exited mitosis without cytokinesis at 36 h after treatment (Figure 5d ). These cells were still tetraploid (4N), but were no longer MPM-2 positive, implying that they had exited mitosis. As multinucleation and tetraploidy are the hallmarks of mitotic slippage, it is likely that several aberrant mitotic cells had slipped out of mitosis (Figure 5d and e) without proceeding through normal anaphase and cytokinesis. Upon exit from mitosis, these cells decondense their chromatin forming multinucleated, pseudo G1-like tetraploid cells (Figure 5e , right).
EM011 induces chronic mitotic delay followed by cell death by multiple fates. Next, we reduced temporal heterogeneity to closely monitor EM011-induced responses by synchronizing HeLa cells at the G1/S boundary. Upon G1/S release, we determined the average time control cells Figure 3) and examined immunostained vehicle-and drug-treated cells for their spindle and nuclear morphologies (Figure 6ai) . At 8 h post release, most drug-treated cells showed numerous microtubule nucleation sites (due to centrosome amplification) evident as distinct bright spots (Figure 6ai ). These typically aberrant G2 cells then rounded up into abnormal multipolar mitotic cells at about 9-10 h and accumulated up to 20 h post release (Figure 6ai) . At 12 h of EM011-treatment post release, several g-tubulin spots (3, 4 or 5) were evident (Figure 6aii (b-d) ). This was in stark contrast to vehicletreated cells that underwent a normal anaphase at 7-8 h, cytokinesis at 8-9 h and progressed into the next interphase at about 9 h post release (Figure 6aiii a-d) .
Next, we quantitated cells in various cell-cycle phases upon drug-treatment post release over time by dual-color flow cytometry (Figure 6bi) . Upon G1/S release, both vehicleand drug-treated cells displayed comparable kinetics of progression through S and G2 phases indicating that EM011 did not affect cell-cycle progression through these phases (Figure 6bi) . However, at B9 h post release, drug-treated cells begin to arrest in mitosis with 4N DNA and positive MPM-2 staining, in contrast to vehicle-treated cells that had transited through mitosis and completed their cell cycle. Drug-treated cells remain stuck in mitosis with MPM-2-positive population peaking at 16 h to B85% (Figure 6bii) . A sub-G1 population at 20 h that continued to accumulate until 24 h indicated apoptosis (Figure 6biii) . Cyclin B1 accumulation commenced at 6 h of drug-treatment post release, and continued to increase until 20 h post release (Figure 6biv) , and declined thereafter (perhaps due to mitotic slippage). Apoptosis induction was confirmed by detection of cleaved caspase-3 and PARP expression (Figure 6biv ) between 12-24 h post release.
Following mitotic arrest, EM011-treated cells display variable cellular outcomes. Consequent to mitotic arrest, cells are consigned to variable fates on the basis of two competing networks, one being cyclin B1 driven and the other being caspase-3 dictated. 36 As our immunoblotting data (in Figure 6biv ) reflect average protein levels within entire cell populations, we comprehended drug-induced outcomes at single-cell level by double immunostaining cells for microtubules and DNA. Drug-treated synchronized cells were microscopically observed after 20 h of drugexposure post release. This time point was chosen as B80-90% cells accumulate in mitosis at 16 h post release. In agreement with the notion of intraline variation, we observed that mitotically arrested cells displayed substantial variation in their ultimate fates. First, cell death was initiated in B10-20% of mitotically arrested cells ( Figure 7A, a-d) . Figure 7A , a-d show mitotic cells with tubulin accumulation in the blebs. Second, B40% (n ¼ 200) cells exited mitosis without cytokinesis into a multinucleate G1-like interphase ( Figure 7A, e) . We also found multinucleated cells succumbing to cell death as indicated by the appearance of highly fragmented nuclei ( Figure 7A, f-g ). We speculate that the unsilenced spindle checkpoint complex might trigger apoptosis in these pseudo-4N G1-like interphase cells. Occasionally, multinucleated cells initiated cell death by blebbing ( Figure 7A, h ). Some cells showed condensed chromatin, reminiscent of apoptotic bodies ( Figure 7A , i-j). We also noted asymmetric cell divisions of Figure 7 (A) Synchronized HeLa cells displayed profound intraline variation in cellular outcomes post mitotic arrest upon EM011 treatment. Mitotic arrest terminated in one of the four ways: cells died while still in mitosis, with blebbing and eventual lysis (a-d); cells slipped from mitosis without cytokinesis, respread and reformed a multinucleate cell (e), cells with micronuclei also evident in some cases (f, g) and blebs beginning to appear in others (h); some cells that slipped simply remained in G1-like interphase, often growing larger, which we interpret as cell-cycle arrest in G1 with 4N DNA. These cells underwent death from the polyploid interphase as evidenced by small fragmented DNA, reminiscent of apoptotic bodies (i, j); cells that escaped mitotic death and slippage aggressively moved ahead to divide asymmetrically into three or four aneuploid daughter cells with abnormal cytoplasmic and nuclear divisions resulting perhaps in inviable karyotypes (k-n) that were death bound as evident by blebbing (o, p). Induction of apoptosis was visualized using immunofluorescence microscopy by increased expression of cleaved caspase-3 (B) and cleaved PARP (C) in drug-treated cells compared with controls upon 20-h treatment post release. Scale bar ¼ 10 mm Figure 7A , k-l). Such divisions often led to asymmetric distribution of cytoplasm (anisocytosis) and DNA (anisokaryosis), which perhaps explain a sub-G1 peak because cells would then have an average of 1.33N DNA instead of 2N DNA and might be inviable. These observations support the idea that high-grade aneuploidy may have a tumor-suppressive and death-promoting role.
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Some drug-treated cells underwent abnormal cytokinesis upon mitotic exit, generating multinucleated daughters containing varying numbers of micronuclei ( Figure 7A , m-n) or occasionally blebs, indicating early apoptosis ( Figure 7A, o-p) . Such abnormal cytokinesis was almost never observed in control cultures, indicating that this does not occur spontaneously in HeLa cells. Furthermore, apoptosis induction was observed by cleaved caspase-3 and PARP immunostaining in synchronized cells that were drug treated for 20 h post release ( Figure 7B and C) . These data thus suggest that EM011-induced high-grade aneuploidy produces an intensely unstable inviable karyotype facilitating cell death.
Induction of spindle multipolarity is crucial for optimal cell death. In order to understand further EM011's mode of action, we determined its 'cytotoxicity-window' by evaluating the cell-cycle phase during which treatment resulted in maximum multipolarity and cell death. We also examined whether spindle multipolarity induction was necessary for maximal cell death. To this end, we designed a phasespecific treatment regimen and exposed synchronized HeLa cells to 25 mM EM011 during the duration of each cell-cycle phase, viz, S, G2 or M-phase, followed by EM011 wash (Figure 8a ). Cells were allowed to continue cell cycle for another 8 h before fixation for flow cytometry and immunostaining. The duration of each cell-cycle phase was determined on the basis of the cell-cycle progression kinetics in synchronized HeLa cells (Supplementary Figure 3) . We observed that the cytotoxic effect of EM011 was maximum (B30% sub-G1) when the drug was applied between 7-11 h post release (i.e., during duration of G2) (Figure 8b,c) . Considerable cell death was also observed in S-phasetreated cells (B15% sub-G1) unlike cells treated in M-phase (B4% sub-G1) (Figure 8c ). To define more precisely the phase-specific drug sensitivity, cell-cycle phases were subdivided into early, mid and late phases, and drug treatment was performed as before (Figure 8d ). This detailed set-up revealed that the most 'critical-window' for drug treatment corresponds to mid and late S and early G2 phases, but not mitosis, as cells appeared quite resistant to cell death when treated in mitosis (Figure 8e) . Moreover, cells treated specifically in S-phase showed multipolar mitotic spindles, whereas cells left untreated in S-phase and treated thereafter rarely showed multipolarity in mitosis (Figure 8f ). This correlation between enhanced spindle multipolarity and apoptosis in S/G2-phase-treated cells tempts us to propose that the deregulation of centrosome duplication cycle and the resulting multipolar spindle morphology are crucial for activating apoptosis in these cells.
Discussion
In this study, we show that EM011, a novel noscapinoid, induces a time-dependent robust mitotic arrest through attenuation of microtubule dynamics, and triggers loss of EB1 and CLIP-170 comets from microtubule plus-ends. As EM011 leaves interphase microtubular virtually unperturbed albeit with reduced dynamicity, it spares the vast majority of post-mitotic cells in vivo, in stark contrast to the non-specific effects of taxanes and vincas. We envision that dampening of microtubule dynamics impairs the ability of mitotic microtubules to capture chromosomes effectively, resulting in a large number of uncongressed chromosomes, increased Aurora B kinase activity, and spindle checkpoint activation in EM011-treated cells. Spindle checkpoint activation in turn prevents anaphase onset and cyclin B destruction, as multipolar cells accumulate in metaphase.
A cell, however, cannot remain arrested in metaphase indefinitely. Our data uncover a high-degree of inherent intraline variation as HeLa cells exhibit diverse fates consequent to EM011-induced mitotic arrest. Mitotic arrest concluded in several different ways perhaps depending on a complex interplay between cell cycle (cyclin B1 and BubR1) and apoptosis (caspase-3 and PARP) regulatory molecules. Some cells showed aberrant multipolar spindles along with extensive plasma membrane blebbing indicating mitotic death. However, we cannot exclude the possibility that cells that succumb to apoptosis during mitotic arrest may have suffered an insult before mitosis. Nonetheless, the appearance of significant sub-G1 population only after 20 h of drug exposure makes any early insult an unlikely cause in apoptosis induction in these cells. Our data instead strongly argue that prolonged metaphase arrest compels cells to seek escape routes that culminate in cell death. Mitotic slippage constitutes one such route in which cyclin B1 levels begin to decline eventually leading to an inappropriate exit from cell cycle. We found that a significant proportion of drug-treated cells slipped out of mitosis without cytokinesis, re-spread and formed massive G1-like interphase cells, often with several micronuclei. We also found an apoptosis-reluctant population that progressed through the cell cycle after mitotic stall to undergo aberrant cytokinesis generating three or four aneuploid daughter cells created by multiple cytokinetic furrows. This supports the emerging paradigm that highlights tremendous complexity in cellular responses to tubulinbinding anticancer drugs consequent to mitotic arrest.
The most remarkable feature of EM011-induced mitotic arrest is hyperamplification of centrosomes and multipolar spindle formation. Although other anti-microtubule drugs, such as like taxanes and nocodazole, also generate multiple spindle poles at low concentrations, they primarily do so by causing pericentriolar matrix fragmentation and not by producing new centrioles. In contrast, EM011-induced spindle poles contained the hallmark components of true centrioles g-tubulin and centrin-2. Furthermore, accumulation of cells with multipolar spindles was accompanied by a surge in Plk4, cyclin E and Aurora A levels in drug-treated cells, suggesting deregulation of centrosome duplication, with lethal consequences. These findings strongly correlate with our observation that EM011 exposure during S-phase was crucial for maximal apoptosis induction. Thus EM011 treatment not only reduces microtubule dynamicity but also leads to a derailment of centrosome duplication cycle, causing inappropriate centrosome amplification.
Previous studies in vertebrate cells carrying extra centrosomes have shown that even though these cells initially form multipolar spindles, supernumerary centrosomes eventually aggregate at two poles resulting in bipolar division. These cells, therefore, rely on centrosome clustering for remaining viable. [6] [7] [8] In contrast, EM011 causes centrosome hyperamplification and spindle multipolarity. EM011-induced centrosome declustering is an extraordinary and unique effect of this drug that perhaps compels cells, after a prolonged mitotic arrest, to undergo multipolar and asymmetric divisions, with catastrophic consequences. Although it is presently unresolved whether dampening of microtubule dynamics and centrosome hyperamplification represent two independent cellular activities of EM011, or whether mechanistic links exist between the two processes, we propose that EM011-induced attenuation of microtubule dynamics directly incapacitates a cellular mechanism for suppressing multipolar mitoses, forcing the cell into a 'suicidal' multipolar division. Such drugs that interfere with centrosome clustering mechanisms could potentially be selectively lethal to tumor cells that are inherently vulnerable to forming extra centrosomes or those that already possess additional centrosomes. In fact, EM011 displays remarkable tumor selectivity in various mice models [16] [17] [18] [19] [20] with no detectable toxicity to tissues with frequently proliferating normal cells. Furthermore, in contrast to the effects of EM011 on HeLa cells as reported in our study herein, the drug had no discernable effect on centrosome numbers or bipolar spindle morphology in non-malignant near-normal breast epithelial cells.
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